Journal of Clinical Epidemiology
Volume 56, Issue 1 , Pages 44-51 , January 2003

How useful are unpublished data from the Food and Drug Administration in meta-analysis?

  • Catherine H MacLean

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: 310-393-0411; fax: 310-451-6917. E-mail address:
    • RAND, 1700 Main Street, M-23C, Santa Monica, CA 90407-2138, USA
    • Department of Medicine, Division of Rheumatology, UCLA School of Medicine, 1000 Veteran Ave., Room 32–48, Los Angeles, CA, USA
    • ,
  • Sally C Morton

      Affiliations

    • RAND, 1700 Main Street, M-23C, Santa Monica, CA 90407-2138, USA
    • ,
  • Joshua J Ofman

      Affiliations

    • Departments of Medicine and Health Services Research, Division of Gastroenterology, Cedars-Sinai Health System, Beverly Blvd., Los Angeles, CA, USA
    • Zynx Health Inc, 9100 Wilshire Blvd., East Tower, Suite 655, Los Angeles, CA, USA
    • ,
  • Elizabeth A Roth

      Affiliations

    • RAND, 1700 Main Street, M-23C, Santa Monica, CA 90407-2138, USA
    • ,
  • Paul G Shekelle

      Affiliations

    • RAND, 1700 Main Street, M-23C, Santa Monica, CA 90407-2138, USA
    • Department of Medicine, West Los Angeles VAMC, 11301 Wilshire Blvd., #111G, Los Angeles, CA, USA
    • Dr. Shekelle is a Senior Research Associate of the Veterans Affairs Health Services Research and Development.
    • ,
  • for the Southern California Evidence-Based Practice Center

Received 15 April 2002 ,Revised 14 June 2002 ,Accepted 23 August 2002.

References 

  1. Cook DJ, Guyatt GH, Ryan G, et al. Should unpublished data be included in meta-analyses? Current convictions and controversies. JAMA 1993;269:2749–53.
  2. Angell M. Negative studies. New Engl J Med. 1989;321:464–466
  3. Data on file. Westport, CT: IMS America.
  4. Moher D, Pham B, Jones A, et al.  Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet. 1998;352:609–613
  5. Schulz KF, Chalmers I, Hayes RJ, et al.  Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408–412
  6. Jadad A, Moore A, Carrol D, et al.  Assessing the quality of reports of randomized clinical trials (is blinding necessary?). Control Clin Trials. 1996;17:1–12
  7. Khan KS, Daya S, Jadad AR. The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med. 1996;156:661–666
  8. Djulbegovic B, Lacevic M, Cantor A, et al.  The uncertainty principle and industry-sponsored research. Lancet. 2000;356:635–638
  9. Dieppe P, Chard J, Tallon D, et al.  Funding clinical research. Lancet. 1999;353:1626
  10. Rochon PA, Gurwitz JH, Simms RW, et al.  A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med. 1994;154:157–163
  11. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297–334
  12. Barbara L, Camilleri M, Corinaldesi R, et al.  Definition and investigation of dyspepsia (consensus of an international ad hoc working party). Dig Dis Sci. 1989;34:1272–1276
  13. Talley NJ, Colin-Jones D, Koch KL, et al.  Functional dyspepsia (a classification with guidelines for diagnosis and management). Gastroenterol Int. 1991;4:146–160
  14. Talley NJ, Silverstein MD, Agreus L, et al.  AGA technical review (evaluation of dyspepsia). Gastroenterology. 1998;114:582–595
  15. Ioannidis JP, Cappelleri JC, Lau J. Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness. Ann Intern Med. 1995;122:856–866
  16. Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care. 1990;6:5–30
  17. Stuck AE, Siu AL, Wieland GD, et al.  Comprehensive geriatric assessment (a meta-analysis of controlled trials). Lancet. 1993;342:1032–1036
  18. Berry H, Bloom B, Hamilton EBD. A comparative study of piroxicam (Feldene), diclofenac and placebo in osteoarthritis. Clin Trials J. 1982;19:349–358
  19. Berry H, Coquelin JP, Gordon A, et al.  Antrafenine, naproxen and placebo in osteoarthritis (a comparative study). Br J Rheumatol. 1983;22:89–94
  20. Brackertz B. Comparative study of sulindac (clinoriland) ibuprofen (brufenin) osteoarthrosis. Br J Clin Pract. 1978;32:77–80
  21. Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum. 1986;29:1371–1377
  22. Hutson MA. A double-blind study comparing ibuprofen 1800 mg or 2400 mg daily and placebo in sports injuries. J Int Med Res. 1986;14:142–147
  23. Jacob GB, Hart KK, Mullane JF. Placebo-controlled study of etodolac and aspirin in the treatment of rheumatoid arthritis. Curr Ther Res Clin Exp. 1983;33:703–713
  24. Lanza FL, Nelson RS, Rack MF. A controlled endoscopic study comparing the toxic effects of sulindac, naproxen, aspirin, and placebo on the gastric mucosa of healthy volunteers. J Clin Pharmacol. 1984;24:89–95
  25. Lanza FL, Rack MF, Royer GLJ. Gastro-intestinal effects of ibuprofen, naproxen and aspirin in normalvolunteers (a comparative study). Clin Trials J. 1986;23:168–177
  26. Mehta S, Dasarathy S, Tandon RK, et al.  A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis. Am J Gastroenterol. 1992;87:996–1000
  27. Ronen S, Rozenman Y, Zylbermann R, et al.  Treatment of ocular inflammation with diclofenac sodium (double-blind trial following cataract surgery). Ann Ophthalmol. 1985;17:577–581
  28. Royer GLJ, Seckman CE, Schwartz JH, et al.  Effects of ibuprofen on normal subjects clinical and routine andspecial laboratory assessments. Curr Ther Res Clin Exp. 1985;37:412–426
  29. Schnitzer TJ, Ballard IM, Constantine G, et al.  Double-blind, placebo-controlled comparison of the safety and efficacy of orally administered etodolac and nabumetone in patients with active osteoarthritis of the knee. Clin Ther. 1995;17:602–612
  30. Stadler P, Armstrong D, Margalith D, et al.  Diclofenac delays healing of gastroduodenal mucosal lesions. Double-blind, placebo-controlled endoscopic study in healthy volunteers. Dig Dis Sci. 1991;36:594–600
  31. Weaver A, Rubin B, Caldwell J, et al.  Comparison of the efficacy and safety of oxaprozin and nabumetone in the treatment of patients with osteoarthritis of the knee. Clin Ther. 1995;17:735–745
  32. Dore R, Ballard I, Constantine G, et al.  Efficacy and safety of Etodolac and Naproxen in patients with osteoarthritis of the knee (a double-blind, placebo-controlled study). Clin Ther. 1995;17:656–666

☆ Supported by a contract from Merck & Co. to RAND.

PII: S0895-4356(02)00520-6

Journal of Clinical Epidemiology
Volume 56, Issue 1 , Pages 44-51 , January 2003

Article Tools

* Image Usage & Resolution